Effets indésirables et conséquences des anti-PD-1 chez les patients très âgés (? 80 ans) traités pour un mélanome métastatique, 2018. ,
, Ann Dermatol Vénéréologie, vol.145, pp.321-322
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, pp.1627-1639, 2015. ,
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination, Nat Rev Clin Oncol, vol.13, pp.473-486, 2016. ,
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, pp.373-383, 1987. ,
Immunotherapy comes of age: Immune aging & checkpoint inhibitors, J Geriatr Oncol, vol.8, pp.229-235, 2017. ,
Measuring comorbidity in older cancer patients, Eur J Cancer Oxf Engl, vol.36, pp.453-471, 1990. ,
Checkpoint inhibition and melanoma: Considerations in treating the older adult, J Geriatr Oncol, vol.8, pp.237-241, 2017. ,
The development of immunotherapy in older adults: New treatments, new toxicities?, J Geriatr Oncol, vol.7, pp.325-333, 2016. ,
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N Engl J Med, vol.363, pp.711-723, 2010. ,
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center, J Clin Oncol, vol.33, pp.3193-3198, 2015. ,
Considerations for successful cancer immunotherapy in aged hosts: Ageing and cancer immunotherapy, Clin Exp Immunol, vol.187, pp.53-63, 2017. ,
Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study, Cancer Immunol Immunother, vol.67, pp.1571-1578, 2018. ,
Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma, J Am Acad Dermatol, vol.72, pp.1036-1046, 2015. ,
Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma, Cancer Immunol Immunother, 2019. ,
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006, J Clin Oncol, vol.36, pp.9503-9503, 2018. ,
Malignant melanoma in the elderly: different regional disease and poorer prognosis, J Cancer, vol.2, pp.538-543, 2011. ,
Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab, J Clin Oncol, vol.34, pp.3047-3047, 2016. ,
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev, vol.45, pp.30-37, 2016. ,
Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma, JAMA Dermatol, vol.154, p.82, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01847410
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma, N Engl J Med, vol.372, pp.2006-2017, 2015. ,
Localized melanoma in older patients, the impact of increasing age and comorbid medical conditions, Eur J Surg Oncol EJSO, vol.42, pp.1359-1366, 2016. ,
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, vol.16, issue.15, pp.83-85, 2015. ,
Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N Engl J Med, vol.372, pp.320-330, 2015. ,
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, N Engl J Med, vol.364, pp.2517-2526, 2011. ,
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label BMS: consultant, Pham-Ledard) dépenses de déplacement congrès, 2017. ,
, MSD: consultant (Beylot-Barry, Dutriaux), honoraires d'orateur (Beylot-Barry, Dutriaux, Pham-Ledard) dépenses de déplacement congrès
Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N Engl J Med, vol.372, pp.320-350, 2015. ,
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, pp.1853-62, 2017. ,
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006, J Clin Oncol, vol.36, p.9503, 2018. ,
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N Engl J Med, vol.377, pp.1345-56, 2017. ,
Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma, Cancer Immunol Immunother, 2019. ,
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, J Exp Clin Cancer Res, vol.33, 2014. ,
Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma, J Immunother Cancer, vol.3, 2015. ,
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma, The Oncologist, vol.22, pp.963-71, 2017. ,
Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients, Crit Rev Oncol Hematol, vol.37, pp.147-52, 2001. ,
Quality of life and survival prediction in terminal cancer patients: A multicenter study, Cancer, vol.101, pp.1090-1098, 2004. ,
The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group Study, Gynecol Oncol, vol.124, pp.379-82, 2012. ,
Quality of Life After Breast Cancer Diagnosis and Survival, J Clin Oncol, vol.29, pp.406-418, 2011. ,
Modalités de recours au dispositifs gériatriques lors de la prise en charge des personnes atteintes de cancer. Spécificité de la prise en charge des patients âgés atteints de cancer. Lyon: Groupe de Recherche Economie de la Santé et Réseaux de soins en Cancérologie, 2006. ,
End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, pp.3711-3719, 2013. ,
Quality-of-life outcomes in patients with advanced melanoma: A review of the literature, Pigment Cell Melanoma Res, vol.30, pp.511-531, 2017. ,
Évolution de la qualité de vie au cours du temps suite à un diagnostic d'un mélanome ou d'un cancer du sein : résultats comparatifs sur deux ans, Ann Dermatol Vénéréologie, vol.144, p.311, 2017. ,
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, pp.373-83, 1987. ,
Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life, Qual Life Res Int J Qual Life Asp Treat Care Rehabil, vol.2, pp.287-95, 1993. ,
Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer, J Eur Acad Dermatol Venereol, 2019. ,
International validation of the EORTC QLQ-ELD14 questionnaire for assessment of healthrelated quality of life elderly patients with cancer, Br J Cancer, vol.109, pp.852-860, 2013. ,
Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study, PloS One, vol.9, p.115060, 2014. ,
Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol Off J Am Soc Clin Oncol, vol.16, pp.139-183, 1998. ,
Decision making and quality of life in the treatment of cancer: a review, Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.17, pp.117-144, 2009. ,
Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma, Acta Oncol Stockh Swed, vol.52, pp.1086-93, 2013. ,
Psychosocial predictors of survival in metastatic melanoma, J Clin Oncol Off J Am Soc Clin Oncol, vol.17, pp.2256-63, 1999. ,
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma, Eur J Cancer Oxf Engl, vol.29, pp.1731-1735, 19901993. ,
Patient reported outcomes for cancer patients receiving immunotherapy: opportunities for palliative care -A Systematic Review, J Pain Symptom Manage, 2019. ,
A systematic review of health-related quality of life in cutaneous melanoma, Ann Oncol Off J Eur Soc Med Oncol, vol.20, issue.6, pp.51-58, 2009. ,
A systematic review examining factors influencing health related quality of life among melanoma cancer survivors, Eur J Cancer, vol.69, pp.189-98, 2016. ,
Management of Cancer in the Older Person: A Practical Approach, The Oncologist, vol.5, pp.224-261, 2000. ,
Quality of life of elderly patients receiving cancer therapy: A systematic review, J Geriatr Oncol, vol.5, p.74, 2014. ,
Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study, Cancer Immunol Immunother, vol.67, pp.1571-1579, 2018. ,
Effets indésirables et conséquences des anti-PD-1 chez les patients très âgés (? 80 ans) traités pour un mélanome métastatique, Ann Dermatol Vénéréologie, vol.145, pp.321-323, 2018. ,
, BIBLIOGRAPHIE 1. Les cancers en France, 2017.
Cancer incidence and mortality in France over the 1980-2012 period: Solid tumors, Rev. DÉpidémiologie Santé Publique, vol.62, pp.95-108, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01915012
, CA. Cancer J. Clin, vol.58, pp.71-96, 2008.
Place des traitements innovants du mélanome métastatique chez le sujet âgé, Ann. Dermatol. Vénéréologie, vol.142, pp.549-556, 2015. ,
Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper, J. Geriatr. Oncol, 2018. ,
Age as a prognostic factor in the malignant melanoma population, Ann. Surg. Oncol, vol.1, pp.487-494, 1994. ,
Distinctive features of melanoma and its management in elderly patients: a population-based study in France, JAMA Dermatol, vol.149, pp.1150-1157, 2013. ,
The clinical diagnosis of early malignant melanoma: expansion of the ABCD criteria to improve diagnostic sensitivity, Dermatol. Online J, vol.5, p.3, 1999. ,
Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting, Br. J. Dermatol, vol.159, pp.669-676, 2008. ,
Detection of desmoplastic melanoma with dermoscopy and reflectance confocal microscopy, J. Eur. Acad. Dermatol. Venereol. JEADV, vol.31, pp.2016-2024, 2017. ,
The classification of malignant melanoma and its histologic reporting, Cancer, vol.32, pp.1446-1457, 1973. ,
Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification, Vivo Athens Greece, vol.28, pp.1005-1011, 2014. ,
Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch. Dermatol, vol.138, pp.609-614, 2002. ,
, Acral Lentiginous Melanoma. Cancer Treat. Res, vol.167, pp.321-329, 2016.
Melanoma in situ: Part I. Epidemiology, screening, and clinical features, J. Am. Acad. Dermatol, vol.73, pp.191-192, 2015. ,
Update on primary mucosal melanoma, J. Am. Acad. Dermatol, vol.71, pp.366-375, 2014. ,
Desmoplastic melanoma: a review, J. Am. Acad. Dermatol, vol.68, pp.825-833, 2013. ,
The clinical behavior of desmoplastic melanoma, Am. J. Surg, vol.182, pp.590-595, 2001. ,
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA, Cancer J. Clin, vol.67, pp.472-492, 2017. ,
Traitements des patients atteints de mélanome de stade III inopérable ou de stade IV. Société française de dermatologie, Ann. Dermatol. Vénéréologie, vol.145, pp.413-422, 2018. ,
CTLA-4: a negative regulator of autoimmune disease, J. Exp. Med, vol.184, pp.783-788, 1996. ,
CTLA-4 ligation blocks CD28-dependent T cell activation, J. Exp. Med, vol.183, pp.2541-2550, 1996. ,
Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma, Proc. Natl. Acad. Sci, vol.100, pp.8372-8377, 2003. ,
Immune-Checkpoints: the new anti-cancer immunotherapies, Bull. Cancer, pp.601-610, 2013. ,
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, N. Engl. J. Med, vol.364, pp.2517-2526, 2011. ,
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N. Engl. J. Med, vol.363, pp.711-723, 2010. ,
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, J. Clin. Oncol, vol.33, pp.1889-1894, 2015. ,
Ipilimumab in the treatment of melanoma, Expert Opin. Biol. Ther, vol.12, pp.773-782, 2012. ,
Management of the cutaneous adverse effects of antimelanoma therapy. Melanoma Manag, vol.4, pp.187-202, 2017. ,
Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study, Eur. J. Dermatol. EJD, vol.27, pp.266-270, 2017. ,
Enterocolitis in patients with cancer after antibody blockade of cytotoxic Tlymphocyte-associated antigen 4, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.2283-2289, 2006. ,
Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma, J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG, vol.9, pp.277-286, 2011. ,
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management, Cancer Treat. Rev, vol.58, pp.70-76, 2017. ,
Immune Checkpoint Inhibitors-Induced Hepatitis, Adv. Exp. Med. Biol, vol.995, pp.159-164, 2018. ,
, Haute autorité de santé. Comission de la transparence, 2017.
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition, Am. J. Clin. Oncol, vol.39, pp.98-106, 2016. ,
PD-1 as a potential target in cancer therapy, Cancer Med, vol.2, pp.662-673, 2013. ,
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs, Int. Immunol, vol.19, pp.1223-1234, 2007. ,
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells, Cancer Res, vol.64, pp.1140-1145, 2004. ,
, ECancer. La situation du cancer en France, 2010.
Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N. Engl. J. Med, vol.372, pp.320-330, 2015. ,
Pembrolizumab versus Ipilimumab in Advanced Melanoma, N. Engl. J. Med, vol.372, pp.2521-2532, 2015. ,
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, pp.1853-1862, 2017. ,
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N. Engl. J. Med, vol.377, pp.1345-1356, 2017. ,
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006, J. Clin. Oncol, vol.36, pp.9503-9503, 2018. ,
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials, JAMA Oncol, vol.3, pp.1511-1519, 2017. ,
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.28, 2002. ,
Evaluation of dosing strategy for pembrolizumab for oncology indications, J. Immunother. Cancer, vol.5, 2017. ,
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001, J. Clin. Oncol, vol.34, pp.9503-9503, 2016. ,
Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment, J. Clin. Oncol, vol.35, pp.9504-9504, 2017. ,
Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression, J. Clin. Oncol, vol.35, pp.9539-9539, 2017. ,
Arrêt des anti-PD1 dans le mélanome métastatique en réponse complète ,
, Ann. Dermatol. Vénéréologie, vol.144, pp.89-90, 2017.
The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma, Melanoma Res, vol.27, pp.168-170, 2017. ,
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma, Ann. Oncol, 2019. ,
, Safety and Tolerability of PD
, L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis, vol.22, pp.470-479, 2017.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, vol.16, pp.908-918, 2015. ,
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade, N. Engl. J. Med, vol.378, pp.158-168, 2018. ,
, Pneumonitis in Patients Treated With Anti-Programmed Death
, Programmed Death Ligand 1 Therapy, J. Clin. Oncol, vol.35, pp.709-717, 2017.
Cutaneous adverse effects of the immune checkpoint inhibitors, Curr. Probl. Cancer, vol.41, pp.125-128, 2017. ,
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1, Cancer Immunol. Res, vol.4, pp.383-389, 2016. ,
, Neurological Complications Associated With Anti-Programmed Death, vol.1
, , vol.74, pp.1216-1222, 2017.
Sarcoïdose pulmonaire induite par le nivolumab, Ann. Dermatol. Vénéréologie, vol.143, pp.359-360, 2016. ,
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treat. Rev, vol.45, pp.7-18, 2016. ,
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann. Oncol, vol.27, pp.559-574, 2016. ,
Toxicité des inhibiteurs de points de contrôle immunitaires, Rev. Mal. Respir, vol.35, pp.1028-1038, 2018. ,
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J. Immunother. Cancer, vol.5, p.95, 2017. ,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann. Oncol, vol.28, pp.119-142, 2017. ,
Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002. ,
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.36, pp.667-673, 2018. ,
Mécanismes de résistance aux inhibiteurs de BRAF, Ann. Dermatol. Vénéréologie, vol.141, pp.671-681, 2014. ,
Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N. Engl. J. Med, vol.364, pp.2507-2516, 2011. ,
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, Lancet Oncol, vol.17, pp.1248-1260, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01407426
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial, Lancet Lond. Engl, vol.380, pp.358-365, 2012. ,
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.28, pp.1631-1639, 2017. ,
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma, N. Engl. J. Med, 2019. ,
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, vol.19, pp.603-615, 2018. ,
Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC, Expert Opin. Drug Saf, vol.12, pp.729-740, 2013. ,
, NPG Neurol. -Psychiatr. -Gériatrie, vol.12, pp.171-181, 2012.
Aging and the skin immune system, Gériatrie Psychol. Neuropsychiatr. Viellissement, vol.7, pp.1256-1262, 1997. ,
Caractérisation phénotypique des lymphocytes T résidents de la peau sénescente, Ann. Dermatol. Vénéréologie, vol.145, p.306, 2018. ,
, Cell Immunosenescence in the Elderly and in Centenarians
, Rejuvenation Res, vol.11, pp.433-439, 2008.
Effects of aging on hematopoietic stem and progenitor cells, Curr. Opin. Immunol, vol.21, pp.408-413, 2009. ,
Immunosenescence of ageing, J. Pathol, vol.211, pp.144-156, 2007. ,
The Effect of Age on Thymic Function, Front. Immunol, vol.4, 2013. ,
The role of the thymus in immunosenescence: lessons from the study of thymectomized individuals, Aging, vol.2, pp.78-81, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-02455362
Aging and Neutrophils: There Is Still Much To Do, Rejuvenation Res, vol.11, pp.873-882, 2008. ,
Human innate immunosenescence: causes and consequences for immunity in old age, Trends Immunol, vol.30, pp.325-333, 2009. ,
GM-CSF activates the Jak/STAT pathway to rescue polymorphonuclear neutrophils from spontaneous apoptosis in young but not elderly individuals, Biogerontology, vol.8, pp.173-187, 2007. ,
Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood, Hum. Immunol, vol.70, pp.777-784, 2009. ,
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response, J. Immunol. Baltim. Md, vol.184, pp.2518-2527, 1950. ,
Elevated levels of tumor necrosis factor alpha and mortality in centenarians, Am. J. Med, vol.115, pp.278-283, 2003. ,
Aged-related shifts in T cell homeostasis lead to intrinsic T cell defects, Semin. Immunol, vol.24, pp.350-355, 2012. ,
Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.18333-18338, 2009. ,
The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age, Clin. Exp. Immunol, vol.140, pp.540-546, 2005. ,
Decreased proliferation, interleukin 2 synthesis, and interleukin 2 receptor expression are accompanied by decreased mRNA expression in phytohemagglutinin-stimulated cells from elderly donors, J. Clin. Invest, vol.81, pp.1096-1102, 1988. ,
Effects of aging on T cell function, Curr. Opin. Immunol, vol.21, pp.414-417, 2009. ,
Aging and immune function: molecular mechanisms to interventions, Antioxid. Redox Signal, vol.14, pp.1551-1585, 2011. ,
Chronic lymphatic leukemia from B CD5+ cells: characteristics, clinical and laboratory features, and immunophenotyping ,
, Pol. Tyg. Lek. Wars. Pol, vol.50, pp.12-14, 1960.
Changes in blood lymphocyte numbers with age in vivo and their association with the levels of cytokines/cytokine receptors, Immun. Ageing A, vol.13, p.24, 2016. ,
Circulating interleukin-6 levels and cardiovascular and all-cause mortality in the elderly population: A meta-analysis, Arch. Gerontol. Geriatr, vol.73, pp.257-262, 2017. ,
Cytomegalovirus Antibody Levels, Inflammation, and Mortality Among Elderly Latinos Over 9 Years of Follow-up, Am. J. Epidemiol, vol.172, pp.363-371, 2010. ,
Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States, PloS One, vol.6, p.16103, 2011. ,
Redefining Chronic Viral Infection, Cell, vol.138, pp.30-50, 2009. ,
Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly, J. Immunol. Baltim. Md, vol.176, pp.2645-2653, 1950. ,
Functional properties of CD4+ CD28-T cells in the aging immune system, Mech. Ageing Dev, vol.102, pp.131-147, 1998. ,
Immunosenescence and novel vaccination strategies for the elderly, Front. Immunol, vol.4, p.171, 2013. ,
Immune checkpoint inhibitors and elderly people: A review, Eur. J. Cancer, vol.82, pp.155-166, 2017. ,
Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging, Cell Metab, vol.18, pp.519-532, 2013. ,
Immune senescence and cancer in elderly patients: results from an exploratory study, Exp. Gerontol, vol.48, pp.1436-1442, 2013. ,
Impaired Dendritic Cell Function in Aging Leads to Defective Antitumor Immunity, Cancer Res, vol.68, pp.6341-6349, 2008. ,
Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort, J. Am. Geriatr. Soc, vol.59, pp.2201-2208, 2011. ,
Does patient age influence anti-cancer immunity?, Semin. Immunopathol, 2018. ,
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab, Clin. Cancer Res, vol.22, pp.2908-2918, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01409624
Cancer Immunotherapies: Are They as Effective in the Elderly?, Drugs Aging, vol.34, pp.567-581, 2017. ,
Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma?, Clin. Cancer Res, vol.24, pp.5193-5194, 2018. ,
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.24, pp.5347-5356, 2018. ,
Age-related autoimmunity, BMC Med, vol.11, 2013. ,
Participation of patients 65 years of age or older in cancer clinical trials, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.21, pp.1383-1389, 2003. ,
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma, The Oncologist, vol.22, pp.963-971, 2017. ,
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, J. Exp. Clin. Cancer Res, vol.33, 2014. ,
Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma, Cancer Immunol. Immunother, 2019. ,
Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma, J. Immunother. Cancer, vol.3, 2015. ,
Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma, Ann. Oncol, vol.27, 2016. ,
Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study, Cancer Immunol. Immunother, vol.67, pp.1571-1578, 2018. ,
Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients, Eur. J. Cancer, vol.108, pp.61-68, 2019. ,
Clinical consequences of polypharmacy in elderly, Expert Opin. Drug Saf, vol.13, pp.57-65, 2014. ,
The development of immunotherapy in older adults: New treatments, new toxicities?, J. Geriatr. Oncol, vol.7, pp.325-333, 2016. ,
Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models, Oncoimmunology, vol.2, p.27186, 2013. ,
Management of immunotherapy toxicities in older adults, Semin. Oncol, vol.45, pp.226-231, 2018. ,
Dying with cancer: The influence of age, comorbidity, and cancer site, Cancer, vol.112, pp.1354-1362, 2008. ,
Checkpoint inhibition and melanoma: Considerations in treating the older adult, J. Geriatr. Oncol, vol.8, pp.237-241, 2017. ,
The Neuropsychiatric Complications of Glucocorticoid Use: Steroid Psychosis Revisited, Psychosomatics, vol.53, pp.103-115, 2012. ,
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.36, pp.1714-1768, 2018. ,
Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study, PLOS Med, vol.13, p.1002024, 2016. ,
, Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL), Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil, vol.2, pp.153-159, 1993.
Quality-of-life outcomes in patients with advanced melanoma: A review of the literature, Pigment Cell Melanoma Res, vol.30, pp.511-520, 2017. ,
The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules, EORTC Study Group on Quality of Life. Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil, vol.2, pp.287-295, 1993. ,
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J. Natl. Cancer Inst, vol.85, pp.365-376, 1993. ,
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, vol.16, pp.375-384, 2015. ,
Health-related quality of life results from the phase III CheckMate 067 study, Eur. J. Cancer, vol.82, pp.80-91, 2017. ,
Management of cancer in the older person: a practical approach, The Oncologist, vol.5, pp.224-237, 2000. ,
Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study, PloS One, vol.9, p.115060, 2014. ,
Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer, Eur. J. Cancer, vol.83, pp.211-219, 2017. ,
A specialized home care intervention improves survival among older postsurgical cancer patients, J. Am. Geriatr. Soc, vol.48, pp.1707-1713, 2000. ,
A comprehensive geriatric intervention detects multiple problems in older breast cancer patients, Crit. Rev. Oncol. Hematol, vol.49, pp.69-75, 2004. ,
Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?, J. Gerontol. A. Biol. Sci. Med. Sci, vol.63, pp.724-730, 2008. ,
Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study, J. Clin. Oncol, vol.29, pp.3636-3642, 2011. ,
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann. Oncol, vol.27, pp.1-27, 2016. ,
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme, Eur. J. Cancer, vol.100, pp.126-134, 2018. ,
The effectiveness of PD-1 inhibitors in nonsmall cell lung cancer (NSCLC) patients of different ages, Oncotarget, vol.9, 2018. ,
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults, Curr. Oncol. Rep, vol.19, 2017. ,
Epidemiology of bladder cancer, Hematol. Oncol. Clin. North Am, vol.29, pp.177-189, 2015. ,
Mutational landscape and significance across 12 major cancer types, Nature, vol.502, pp.333-339, 2013. ,
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer, OncoTargets Ther, vol.11, pp.5973-5989, 2018. ,
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N. Engl. J. Med, vol.376, pp.1015-1026, 2017. ,
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy, Lancet Oncol, vol.12, pp.211-214, 2011. ,
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, singlearm, phase 2 study, Lancet Oncol, vol.18, pp.1483-1492, 2017. ,
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, vol.18, pp.312-322, 2017. ,
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab, Ann. Oncol, vol.443, 2016. ,
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors: Sequencing of Melanoma Therapies, Cancer, vol.120, pp.1695-1701, 2014. ,
Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma, BMC Cancer, vol.18, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01911405
Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data, BMC Cancer, vol.18, 2018. ,
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis, Lancet Oncol, vol.19, pp.310-322, 2018. ,
Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives, JNCI J. Natl. Cancer Inst, vol.108, 2016. ,
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials, Ther. Adv. Med. Oncol, vol.11, p.175883591983082, 2019. ,
Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance, Pharmacol. Res, vol.123, pp.95-102, 2017. ,
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab, N. Engl. J. Med, vol.368, pp.1365-1366, 2013. ,
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma, J. Clin. Oncol, vol.33, pp.3003-3003, 2015. ,
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity, J. Clin. Oncol, vol.35, pp.3063-3063, 2017. ,
1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma, Ann. Oncol, vol.29, 2018. ,
Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM), J. Clin. Oncol, vol.36, pp.9560-9560, 2018. ,
Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma, J. Clin. Oncol, vol.36, pp.189-189, 2018. ,
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program, Cancer Invest, vol.32, pp.144-149, 2014. ,
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain, N. Engl. J. Med, vol.379, pp.722-730, 2018. ,
Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort, J. Clin. Oncol, vol.34, pp.9506-9506, 2016. ,
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.35, pp.3807-3814, 2017. ,
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma, Ann. Oncol, vol.29, pp.250-255, 2018. ,
Hospitalisation costs of metastatic melanoma in France; the MELISSA study, MELanoma In hoSpital coSts Assessment). BMC Health Serv. Res, vol.17, 2017. ,
Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly, Am. Health Drug Benefits, vol.11, pp.334-343, 2018. ,
Cancer incidence and mortality in France over the 1980-2012 period: Solid tumors, Rev. DÉpidémiologie Santé Publique, vol.62, pp.95-108, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01915012
, CA. Cancer J. Clin, vol.58, pp.71-96, 2008.
Place des traitements innovants du mélanome métastatique chez le sujet âgé, Ann. Dermatol. Vénéréologie, vol.142, pp.549-556, 2015. ,
Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper, J. Geriatr. Oncol, 2018. ,
Age as a prognostic factor in the malignant melanoma population, Ann. Surg. Oncol, vol.1, pp.487-494, 1994. ,
Distinctive features of melanoma and its management in elderly patients: a population-based study in France, JAMA Dermatol, vol.149, pp.1150-1157, 2013. ,
The clinical diagnosis of early malignant melanoma: expansion of the ABCD criteria to improve diagnostic sensitivity, Dermatol. Online J, vol.5, p.3, 1999. ,
Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting, Br. J. Dermatol, vol.159, pp.669-676, 2008. ,
Detection of desmoplastic melanoma with dermoscopy and reflectance confocal microscopy, J. Eur. Acad. Dermatol. Venereol. JEADV, vol.31, pp.2016-2024, 2017. ,
The classification of malignant melanoma and its histologic reporting, Cancer, vol.32, pp.1446-1457, 1973. ,
Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification, Vivo Athens Greece, vol.28, pp.1005-1011, 2014. ,
Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch. Dermatol, vol.138, pp.609-614, 2002. ,
, Acral Lentiginous Melanoma. Cancer Treat. Res, vol.167, pp.321-329, 2016.
Melanoma in situ: Part I. Epidemiology, screening, and clinical features, J. Am. Acad. Dermatol, vol.73, pp.191-192, 2015. ,
Update on primary mucosal melanoma, J. Am. Acad. Dermatol, vol.71, pp.366-375, 2014. ,
Desmoplastic melanoma: a review, J. Am. Acad. Dermatol, vol.68, pp.825-833, 2013. ,
The clinical behavior of desmoplastic melanoma, Am. J. Surg, vol.182, pp.590-595, 2001. ,
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA, Cancer J. Clin, vol.67, pp.472-492, 2017. ,
Traitements des patients atteints de mélanome de stade III inopérable ou de stade IV. Société française de dermatologie, Ann. Dermatol. Vénéréologie, vol.145, pp.413-422, 2018. ,
CTLA-4: a negative regulator of autoimmune disease, J. Exp. Med, vol.184, pp.783-788, 1996. ,
CTLA-4 ligation blocks CD28-dependent T cell activation, J. Exp. Med, vol.183, pp.2541-2550, 1996. ,
Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma, Proc. Natl. Acad. Sci, vol.100, pp.8372-8377, 2003. ,
Immune-Checkpoints: the new anti-cancer immunotherapies, Bull. Cancer, pp.601-610, 2013. ,
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, N. Engl. J. Med, vol.364, pp.2517-2526, 2011. ,
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N. Engl. J. Med, vol.363, pp.711-723, 2010. ,
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, J. Clin. Oncol, vol.33, pp.1889-1894, 2015. ,
Ipilimumab in the treatment of melanoma, Expert Opin. Biol. Ther, vol.12, pp.773-782, 2012. ,
Management of the cutaneous adverse effects of antimelanoma therapy. Melanoma Manag, vol.4, pp.187-202, 2017. ,
Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study, Eur. J. Dermatol. EJD, vol.27, pp.266-270, 2017. ,
Enterocolitis in patients with cancer after antibody blockade of cytotoxic Tlymphocyte-associated antigen 4, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.2283-2289, 2006. ,
Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma, J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG, vol.9, pp.277-286, 2011. ,
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management, Cancer Treat. Rev, vol.58, pp.70-76, 2017. ,
Immune Checkpoint Inhibitors-Induced Hepatitis, Adv. Exp. Med. Biol, vol.995, pp.159-164, 2018. ,
, Haute autorité de santé. Comission de la transparence, 2017.
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition, Am. J. Clin. Oncol, vol.39, pp.98-106, 2016. ,
PD-1 as a potential target in cancer therapy, Cancer Med, vol.2, pp.662-673, 2013. ,
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs, Int. Immunol, vol.19, pp.1223-1234, 2007. ,
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells, Cancer Res, vol.64, pp.1140-1145, 2004. ,
, ECancer. La situation du cancer en France, 2010.
Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N. Engl. J. Med, vol.372, pp.320-330, 2015. ,
Pembrolizumab versus Ipilimumab in Advanced Melanoma, N. Engl. J. Med, vol.372, pp.2521-2532, 2015. ,
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, pp.1853-1862, 2017. ,
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N. Engl. J. Med, vol.377, pp.1345-1356, 2017. ,
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006, J. Clin. Oncol, vol.36, pp.9503-9503, 2018. ,
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials, JAMA Oncol, vol.3, pp.1511-1519, 2017. ,
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.28, 2002. ,
Evaluation of dosing strategy for pembrolizumab for oncology indications, J. Immunother. Cancer, vol.5, 2017. ,
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001, J. Clin. Oncol, vol.34, pp.9503-9503, 2016. ,
Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment, J. Clin. Oncol, vol.35, pp.9504-9504, 2017. ,
Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression, J. Clin. Oncol, vol.35, pp.9539-9539, 2017. ,
Arrêt des anti-PD1 dans le mélanome métastatique en réponse complète ,
, Ann. Dermatol. Vénéréologie, vol.144, pp.89-90, 2017.
The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma, Melanoma Res, vol.27, pp.168-170, 2017. ,
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma, Ann. Oncol, 2019. ,
, Safety and Tolerability of PD
, L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis, vol.22, pp.470-479, 2017.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, vol.16, pp.908-918, 2015. ,
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade, N. Engl. J. Med, vol.378, pp.158-168, 2018. ,
, Pneumonitis in Patients Treated With Anti-Programmed Death
, Programmed Death Ligand 1 Therapy, J. Clin. Oncol, vol.35, pp.709-717, 2017.
Cutaneous adverse effects of the immune checkpoint inhibitors, Curr. Probl. Cancer, vol.41, pp.125-128, 2017. ,
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1, Cancer Immunol. Res, vol.4, pp.383-389, 2016. ,
, Neurological Complications Associated With Anti-Programmed Death, vol.1
, , vol.74, pp.1216-1222, 2017.
Sarcoïdose pulmonaire induite par le nivolumab, Ann. Dermatol. Vénéréologie, vol.143, pp.359-360, 2016. ,
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treat. Rev, vol.45, pp.7-18, 2016. ,
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann. Oncol, vol.27, pp.559-574, 2016. ,
Toxicité des inhibiteurs de points de contrôle immunitaires, Rev. Mal. Respir, vol.35, pp.1028-1038, 2018. ,
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J. Immunother. Cancer, vol.5, p.95, 2017. ,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann. Oncol, vol.28, pp.119-142, 2017. ,
Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002. ,
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.36, pp.667-673, 2018. ,
Mécanismes de résistance aux inhibiteurs de BRAF, Ann. Dermatol. Vénéréologie, vol.141, pp.671-681, 2014. ,
Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N. Engl. J. Med, vol.364, pp.2507-2516, 2011. ,
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, Lancet Oncol, vol.17, pp.1248-1260, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01407426
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial, Lancet Lond. Engl, vol.380, pp.358-365, 2012. ,
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.28, pp.1631-1639, 2017. ,
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma, N. Engl. J. Med, 2019. ,
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, vol.19, pp.603-615, 2018. ,
Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC, Expert Opin. Drug Saf, vol.12, pp.729-740, 2013. ,
, NPG Neurol. -Psychiatr. -Gériatrie, vol.12, pp.171-181, 2012.
Aging and the skin immune system, Gériatrie Psychol. Neuropsychiatr. Viellissement, vol.7, pp.1256-1262, 1997. ,
Caractérisation phénotypique des lymphocytes T résidents de la peau sénescente, Ann. Dermatol. Vénéréologie, vol.145, p.306, 2018. ,
B Cell Immunosenescence in the Elderly and in Centenarians, Rejuvenation Res, vol.11, pp.433-439, 2008. ,
Effects of aging on hematopoietic stem and progenitor cells, Curr. Opin. Immunol, vol.21, pp.408-413, 2009. ,
Immunosenescence of ageing, J. Pathol, vol.211, pp.144-156, 2007. ,
The Effect of Age on Thymic Function, Front. Immunol, vol.4, 2013. ,
The role of the thymus in immunosenescence: lessons from the study of thymectomized individuals, Aging, vol.2, pp.78-81, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-02455362
Aging and Neutrophils: There Is Still Much To Do, Rejuvenation Res, vol.11, pp.873-882, 2008. ,
Human innate immunosenescence: causes and consequences for immunity in old age, Trends Immunol, vol.30, pp.325-333, 2009. ,
GM-CSF activates the Jak/STAT pathway to rescue polymorphonuclear neutrophils from spontaneous apoptosis in young but not elderly individuals, Biogerontology, vol.8, pp.173-187, 2007. ,
Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood, Hum. Immunol, vol.70, pp.777-784, 2009. ,
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response, J. Immunol. Baltim. Md, vol.184, pp.2518-2527, 1950. ,
Elevated levels of tumor necrosis factor alpha and mortality in centenarians, Am. J. Med, vol.115, pp.278-283, 2003. ,
Aged-related shifts in T cell homeostasis lead to intrinsic T cell defects, Semin. Immunol, vol.24, pp.350-355, 2012. ,
Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.18333-18338, 2009. ,
The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age, Clin. Exp. Immunol, vol.140, pp.540-546, 2005. ,
Decreased proliferation, interleukin 2 synthesis, and interleukin 2 receptor expression are accompanied by decreased mRNA expression in phytohemagglutinin-stimulated cells from elderly donors, J. Clin. Invest, vol.81, pp.1096-1102, 1988. ,
Effects of aging on T cell function, Curr. Opin. Immunol, vol.21, pp.414-417, 2009. ,
Aging and immune function: molecular mechanisms to interventions, Antioxid. Redox Signal, vol.14, pp.1551-1585, 2011. ,
Chronic lymphatic leukemia from B CD5+ cells: characteristics, clinical and laboratory features, and immunophenotyping ,
, Pol. Tyg. Lek. Wars. Pol, vol.50, pp.12-14, 1960.
Changes in blood lymphocyte numbers with age in vivo and their association with the levels of cytokines/cytokine receptors, Immun. Ageing A, vol.13, p.24, 2016. ,
Circulating interleukin-6 levels and cardiovascular and all-cause mortality in the elderly population: A meta-analysis, Arch. Gerontol. Geriatr, vol.73, pp.257-262, 2017. ,
Cytomegalovirus Antibody Levels, Inflammation, and Mortality Among Elderly Latinos Over 9 Years of Follow-up, Am. J. Epidemiol, vol.172, pp.363-371, 2010. ,
Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States, PloS One, vol.6, p.16103, 2011. ,
Redefining Chronic Viral Infection, Cell, vol.138, pp.30-50, 2009. ,
Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly, J. Immunol. Baltim. Md, vol.176, pp.2645-2653, 1950. ,
Functional properties of CD4+ CD28-T cells in the aging immune system, Mech. Ageing Dev, vol.102, pp.131-147, 1998. ,
Immunosenescence and novel vaccination strategies for the elderly, Front. Immunol, vol.4, p.171, 2013. ,
Immune checkpoint inhibitors and elderly people: A review, Eur. J. Cancer, vol.82, pp.155-166, 2017. ,
Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging, Cell Metab, vol.18, pp.519-532, 2013. ,
Immune senescence and cancer in elderly patients: results from an exploratory study, Exp. Gerontol, vol.48, pp.1436-1442, 2013. ,
Impaired Dendritic Cell Function in Aging Leads to Defective Antitumor Immunity, Cancer Res, vol.68, pp.6341-6349, 2008. ,
Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort, J. Am. Geriatr. Soc, vol.59, pp.2201-2208, 2011. ,
Does patient age influence anti-cancer immunity?, Semin. Immunopathol, 2018. ,
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab, Clin. Cancer Res, vol.22, pp.2908-2918, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01409624
Cancer Immunotherapies: Are They as Effective in the Elderly?, Drugs Aging, vol.34, pp.567-581, 2017. ,
Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma?, Clin. Cancer Res, vol.24, pp.5193-5194, 2018. ,
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.24, pp.5347-5356, 2018. ,
Age-related autoimmunity, BMC Med, vol.11, 2013. ,
Participation of patients 65 years of age or older in cancer clinical trials, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.21, pp.1383-1389, 2003. ,
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma, The Oncologist, vol.22, pp.963-971, 2017. ,
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, J. Exp. Clin. Cancer Res, vol.33, 2014. ,
Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma, Cancer Immunol. Immunother, 2019. ,
Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma, J. Immunother. Cancer, vol.3, 2015. ,
Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma, Ann. Oncol, vol.27, 2016. ,
Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study, Cancer Immunol. Immunother, vol.67, pp.1571-1578, 2018. ,
Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients, Eur. J. Cancer, vol.108, pp.61-68, 2019. ,
Clinical consequences of polypharmacy in elderly, Expert Opin. Drug Saf, vol.13, pp.57-65, 2014. ,
The development of immunotherapy in older adults: New treatments, new toxicities?, J. Geriatr. Oncol, vol.7, pp.325-333, 2016. ,
Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models, Oncoimmunology, vol.2, p.27186, 2013. ,
Management of immunotherapy toxicities in older adults, Semin. Oncol, vol.45, pp.226-231, 2018. ,
Dying with cancer: The influence of age, comorbidity, and cancer site, Cancer, vol.112, pp.1354-1362, 2008. ,
Checkpoint inhibition and melanoma: Considerations in treating the older adult, J. Geriatr. Oncol, vol.8, pp.237-241, 2017. ,
The Neuropsychiatric Complications of Glucocorticoid Use: Steroid Psychosis Revisited, Psychosomatics, vol.53, pp.103-115, 2012. ,
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.36, pp.1714-1768, 2018. ,
Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study, PLOS Med, vol.13, p.1002024, 2016. ,
, Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL), Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil, vol.2, pp.153-159, 1993.
Quality-of-life outcomes in patients with advanced melanoma: A review of the literature, Pigment Cell Melanoma Res, vol.30, pp.511-520, 2017. ,
The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules, EORTC Study Group on Quality of Life. Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil, vol.2, pp.287-295, 1993. ,
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J. Natl. Cancer Inst, vol.85, pp.365-376, 1993. ,
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, vol.16, pp.375-384, 2015. ,
Health-related quality of life results from the phase III CheckMate 067 study, Eur. J. Cancer, vol.82, pp.80-91, 2017. ,
Management of cancer in the older person: a practical approach, The Oncologist, vol.5, pp.224-237, 2000. ,
Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study, PloS One, vol.9, p.115060, 2014. ,
Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer, Eur. J. Cancer, vol.83, pp.211-219, 2017. ,
A specialized home care intervention improves survival among older postsurgical cancer patients, J. Am. Geriatr. Soc, vol.48, pp.1707-1713, 2000. ,
A comprehensive geriatric intervention detects multiple problems in older breast cancer patients, Crit. Rev. Oncol. Hematol, vol.49, pp.69-75, 2004. ,
Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?, J. Gerontol. A. Biol. Sci. Med. Sci, vol.63, pp.724-730, 2008. ,
Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study, J. Clin. Oncol, vol.29, pp.3636-3642, 2011. ,
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann. Oncol, vol.27, pp.1-27, 2016. ,
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme, Eur. J. Cancer, vol.100, pp.126-134, 2018. ,
The effectiveness of PD-1 inhibitors in nonsmall cell lung cancer (NSCLC) patients of different ages, Oncotarget, vol.9, 2018. ,
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults, Curr. Oncol. Rep, vol.19, 2017. ,
Epidemiology of bladder cancer, Hematol. Oncol. Clin. North Am, vol.29, pp.177-189, 2015. ,
Mutational landscape and significance across 12 major cancer types, Nature, vol.502, pp.333-339, 2013. ,
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer, OncoTargets Ther, vol.11, pp.5973-5989, 2018. ,
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N. Engl. J. Med, vol.376, pp.1015-1026, 2017. ,
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy, Lancet Oncol, vol.12, pp.211-214, 2011. ,
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, singlearm, phase 2 study, Lancet Oncol, vol.18, pp.1483-1492, 2017. ,
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, vol.18, pp.312-322, 2017. ,
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab, Ann. Oncol, vol.443, 2016. ,
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors: Sequencing of Melanoma Therapies, Cancer, vol.120, pp.1695-1701, 2014. ,
Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma, BMC Cancer, vol.18, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01911405
Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data, BMC Cancer, vol.18, 2018. ,
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis, Lancet Oncol, vol.19, pp.310-322, 2018. ,
Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives, JNCI J. Natl. Cancer Inst, vol.108, 2016. ,
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials, Ther. Adv. Med. Oncol, vol.11, p.175883591983082, 2019. ,
Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance, Pharmacol. Res, vol.123, pp.95-102, 2017. ,
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab, N. Engl. J. Med, vol.368, pp.1365-1366, 2013. ,
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma, J. Clin. Oncol, vol.33, pp.3003-3003, 2015. ,
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity, J. Clin. Oncol, vol.35, pp.3063-3063, 2017. ,
1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma, Ann. Oncol, vol.29, 2018. ,
Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM), J. Clin. Oncol, vol.36, pp.9560-9560, 2018. ,
Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma, J. Clin. Oncol, vol.36, pp.189-189, 2018. ,
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program, Cancer Invest, vol.32, pp.144-149, 2014. ,
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain, N. Engl. J. Med, vol.379, pp.722-730, 2018. ,
Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort, J. Clin. Oncol, vol.34, pp.9506-9506, 2016. ,
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.35, pp.3807-3814, 2017. ,
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma, Ann. Oncol, vol.29, pp.250-255, 2018. ,
Hospitalisation costs of metastatic melanoma in France; the MELISSA study, MELanoma In hoSpital coSts Assessment). BMC Health Serv. Res, vol.17, 2017. ,
Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly, Am. Health Drug Benefits, vol.11, pp.334-343, 2018. ,